Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orthofix Medical (OFIX) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Orthofix Medical (OFIX) over the last 15 years, with Q3 2025 value amounting to $12.7 million.

  • Orthofix Medical's Change in Accured Expenses rose 7885.18% to $12.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.3 million, marking a year-over-year increase of 17440.53%. This contributed to the annual value of $9.5 million for FY2024, which is 13413.62% up from last year.
  • Orthofix Medical's Change in Accured Expenses amounted to $12.7 million in Q3 2025, which was up 7885.18% from -$378000.0 recorded in Q2 2025.
  • Over the past 5 years, Orthofix Medical's Change in Accured Expenses peaked at $12.7 million during Q3 2025, and registered a low of -$21.4 million during Q1 2025.
  • Over the past 5 years, Orthofix Medical's median Change in Accured Expenses value was $2.9 million (recorded in 2022), while the average stood at $325473.7.
  • Examining YoY changes over the last 5 years, Orthofix Medical's Change in Accured Expenses showed a top increase of 203047.21% in 2021 and a maximum decrease of 47906.98% in 2021.
  • Quarter analysis of 5 years shows Orthofix Medical's Change in Accured Expenses stood at $5.0 million in 2021, then grew by 4.71% to $5.2 million in 2022, then fell by 21.34% to $4.1 million in 2023, then skyrocketed by 203.18% to $12.4 million in 2024, then increased by 2.53% to $12.7 million in 2025.
  • Its Change in Accured Expenses stands at $12.7 million for Q3 2025, versus -$378000.0 for Q2 2025 and -$21.4 million for Q1 2025.